Regranex

Selected form

Becaplermin

Method of action: Preparations For Treatment Of Wounds And Ulcers

Treatment option: Diabetic Neuropathic Ulcers, Infection, Bedsores, Debridement

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Regranex

Quick Facts

Property	Description
Active ingredient	Becaplermin (rhPDGF-BB)
Form	Preserved Topical Gel (0.01% strength)
Pharmacological class	Human Platelet-derived Growth Factor, Cicatrizant
General purpose	Adjunct therapy to promote wound healing
Origin	Recombinant DNA technology product

What Type of Medicine is Regranex?

Regranex is a prescription-only (Rx) specialized Wound Care Agent for topical use. Its active component is Becaplermin, which is classified as a Human Platelet-derived Growth Factor. This protein belongs to the broader pharmacological category of Cicatrizants.

This medication is designed to provide a targeted biological signal, positioning it as a sophisticated therapeutic resource that mimics the function of the endogenous Platelet-Derived Growth Factor (PDGF) naturally released by the body at an injury site. The final drug is supplied as a 0.01% topical gel that is applied directly to the affected area.

Composition and Biological Origin

The key component, Becaplermin, is technically known as recombinant human Platelet-Derived Growth Factor-BB (rhPDGF-BB). The term "recombinant" indicates that this molecule is an exogenous protein produced using advanced recombinant DNA technology. This process ensures a consistent and specific biological agent that is distinct from traditional small-molecule drugs.

This unique biological mechanism allows the drug to actively engage cellular receptors in the wound bed. The preserved hydrogel vehicle ensures stable, localized delivery of the rhPDGF-BB, which is critical for its function as a Cell Stimulant and Proliferant.

General Purpose and Healing Action

The overall purpose of Regranex is to serve as an adjunct therapy to help accelerate and enhance the body’s own healing process in chronic, non-healing wounds. It is clinically recognized for its ability to drive new tissue growth, a process often stalled in chronic conditions.

Its action involves stimulating key biological pathways, which leads to the chemotactic recruitment of cells and their subsequent cellular proliferation. This mechanism directly boosts the formation of robust granulation tissue, the fundamental connective tissue necessary to fill and close open wounds. By actively supplying this crucial growth factor, the medicine helps expedite wound closure when used alongside standard care practices.

What side effects are possible with Regranex?

Possible Side Effects and Safety Information

The official safety information for Regranex is categorized into common application-site reactions and critical systemic safety concerns, as documented in regulatory prescribing information.

Adverse Reactions and Frequencies

Adverse reactions reported in clinical data are grouped by frequency, predominantly affecting the Infections and Infestations and General Disorders and Administration Site Conditions system-organ classes.

Classification	Adverse Reaction	System-Organ Class
More Common (Observed in >10% of patients)	Wound infection	Infections and Infestations
Less Common (Observed in 1–10% of patients)	Erythematous rash, Skin irritation, Pain at application site	General Disorders and Administration Site Conditions

Critical Systemic Safety Concern

Regulatory documents highlight a specific serious safety risk regarding Malignant Neoplasms. The official prescribing information includes a Boxed Warning that reports an increased rate of death from malignancy (cancer) in patients who received a high cumulative dose (three or more tubes) of the gel. This critical finding establishes a specific dose- and duration-related safety pattern.

Population-Specific Restrictions

The use of Regranex is formally contraindicated in specific patient populations. It must not be used in individuals with a known active malignancy at the application site. It is also contraindicated in patients with a known hypersensitivity to any component of the formulation. These restrictions serve to manage the overall risk profile established by the official labeling.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Regranex overdose is characterized by the drug's properties as a topical agent with negligible systemic absorption. Regulatory authorities note that data on the effects of becaplermin overdose are limited, and the FDA states there are no data available regarding the clinical effects of topical excess.

This lack of expected risk is based on the finding that systemic absorption from the topical application site is insignificant. Therefore, regulatory documentation indicates that no untoward systemic events are expected from using an amount of the gel greater than prescribed. Using an excess amount has also not been shown to be beneficial.

When to Seek Immediate Medical Help

The official guidance emphasizes that the product is strictly for topical use and is not for oral, ophthalmic, or intravaginal use. Urgent medical attention must be sought if the gel is used outside of its approved topical route, most notably in the event of accidental ingestion. The label does not list a specific antidote for becaplermin overdose, nor does it describe specific procedural management steps for overdose situations.

Therapeutic Uses of Regranex

What Regranex Treats: Main Uses and Benefits

Regranex is used in situations involving certain distressing symptoms, primarily focusing on chronic, deep sores on the lower extremities associated with diabetes. The medication is applied across domains where additional symptomatic support is needed, primarily focusing on lower extremity diabetic neuropathic ulcers.

Regranex is used to help manage impaired wound closure and address the symptom of localized tissue deficit. It is relevant in conditions characterized by periods of heightened symptoms and requiring additional assistance. The goal is to address symptom clusters that may become intense or disruptive, which contributes to easing the overall symptom load and helps improve day-to-day comfort.

“The medication is used in situations involving certain distressing symptoms linked to tissue deficits.”

Quick Fact: Relief for Impaired Wound Closure

Regranex is considered relevant when chronic, deep sores associated with diabetes create noticeable functional strain and require supportive relief to support the management of symptoms.

Regulatory References

U.S. Food and Drug Administration (FDA) label for Regranex

Eligibility and Restrictions for Use

Who can and cannot use Regranex?

Eligibility to use Regranex (becaplermin) is strictly defined by regulatory authorities based on patient population, specific wound type, and absolute contraindications.

Contraindicated Populations

Regranex is contraindicated (must not be used) in patients who have a known neoplasm (cancer) present directly at the site of the ulcer application. It is also prohibited for individuals with a known hypersensitivity or allergy to becaplermin or any other component of the topical gel formulation. Use requires caution in patients with a malignancy distant from the wound site.

Restricted and Non-Established Use

Wound Conditions: The medicine is intended solely for lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or deeper, and the ulcer must be free of infection before treatment begins. Efficacy has not been established for the treatment of pressure ulcers or venous stasis ulcers.

Age and Development: Safety and effectiveness have not been established in pediatric patients below the age of 16 (or 18 in some regions). Regranex is not recommended for use during pregnancy or lactation due to a lack of sufficient human safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regranex (becaplermin) is a recombinant human growth factor applied as a topical gel, and its official regulatory profile is characterized by a general absence of documented systemic interactions. Because the drug exhibits negligible systemic absorption following topical administration, there are no known or documented pharmacokinetic interactions with systemic medicinal products.

Documented Absence of Systemic Interactions

Interaction Type	Official Regulatory Status
Pharmacokinetic (e.g., CYP)	No formal studies documented; no known systemic interactions.
Pharmacodynamic	No additive or synergistic effects documented with systemic medicines.
Food, Alcohol, Herbal Products	No interactions documented in official prescribing information.

Local Interaction Restrictions

While systemic interactions are not known, regulatory documents address the potential for local interactions at the application site. Official prescribing information states that it is not known if Regranex interacts with other topical medications applied to the ulcer. Due to this lack of study data, a mandatory restriction exists: Regranex should not be applied to the ulcer site in conjunction with other topical medications.

Contraindicated Combinations

No systemic medicinal products are explicitly classified as contraindicated combinations with Regranex based on a known pharmacokinetic or pharmacodynamic interaction.

Mechanism of Action

Regranex contains becaplermin, a recombinant form of the human growth factor, Platelet-Derived Growth Factor-BB (PDGF-BB). This protein functions as an agonist by selectively targeting and binding to the PDGF receptor beta (PDGFR-beta), a tyrosine kinase receptor expressed on the surface of various cell types, including fibroblasts, smooth muscle cells, and endothelial cells.

Upon ligand binding, the PDGF-beta receptors undergo dimerization and subsequent autophosphorylation of their intracellular domains. This event initiates an intracellular signaling cascade by recruiting and activating downstream effector proteins. Key pathways modulated include the PI3K/Akt and Ras/MAPK pathways. Modulation of these pathways promotes chemotactic recruitment and proliferation of cells essential for physiological tissue reconstruction, specifically fibroblasts and macrophages. Furthermore, activation of the PDGF receptor contributes to angiogenesis (new blood vessel formation) by stimulating endothelial cell proliferation. This collective cellular and vascular activity leads to the enhanced formation of granulation tissue, a system-level physiological modulation that supports tissue structure and integrity at the site of application.

Dosage and Administration Information

The administration of Regranex (becaplermin) gel is governed by a highly specific, standardized procedure. The approved route of administration is topical, applied directly to the wound surface.

Dosing and Frequency

The dose is not fixed but is precisely calculated daily based on the measured length times width of the specific ulcer area, resulting in a thin layer of 0.01% gel. This calculated amount is applied once daily (every 24 hours). The medicine is consistently used as an adjunct therapy alongside comprehensive ulcer care, including surgical debridement and pressure relief.

Procedural Application Steps

Before application, the ulcer must be cleaned and rinsed with saline or water. A mandatory 30-minute interval must elapse between this cleansing step and the application of the gel. The thin layer of calculated gel is spread across the entire ulcer, ensuring the tube opening never touches the wound or any other surface to prevent contamination. After application, the area must be immediately covered with a saline-moistened non-adherent dressing. This dressing is removed, and the wound is rinsed again, approximately 12 hours after the gel was applied.

Course Duration and Limits

Treatment is intended to continue until the ulcer is completely healed, but it must not exceed 20 weeks. Furthermore, the protocol requires discontinuation if the ulcer size has not been reduced by at least 30% after 10 weeks of continuous, daily use. If a dose is missed, it should be applied as soon as the patient remembers, and the normal daily schedule should be resumed the following day.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Regranex

Investigational Use in Chronic Wounds/Ulcers

Research has explored the use of Regranex in the context of chronic wounds, such as those associated with diabetes. This research has been applied in studies examining patient-reported experiences and outcomes related to systemic or functional imbalance.

In these studies, Regranex was studied for its ability to assess outcomes related to wound changes. The evidence derived from these settings often describes patterns related to changes in the area and depth of the wounds over defined time intervals. Many findings describe patterns observed in the studies showing that, when compared to a placebo gel, data showed patterns related to differences in the rate of complete healing within the study period. This is often an outcome reflecting daily functioning or activity level that research has monitored.

However, evidence is limited, and findings were mixed in some trials. Research highlights changes measured during the study period, but results apply only to the populations studied, and long-term effects are not fully established. Comparative evidence is lacking to definitively assess how this approach compares to all other available treatments for this condition marked by functional limitations. The findings help contextualize how patients reported their experience, but certainty remains low regarding individual outcomes.

Evidence for Diabetic Neuropathic Ulcers (DNUs)

For the specific population with Diabetic Neuropathic Ulcers, research has focused on those conditions associated with acute or disruptive episodes and functional limitations stemming from chronic diabetes. These trials were relevant in trials assessing short-term or episodic symptom patterns and studies observing responses over defined time intervals.

Multiple controlled studies have explored the effect of Regranex when added to standard wound care (like debridement and pressure relief). The data show patterns related to outcomes related to physical discomfort and systemic imbalance. Specifically, studies report how symptoms evolved in the observed populations, and the use of the gel research monitored differences in the rate of complete wound closure during the observation period compared to standard care alone. This type of research examined outcomes reflecting daily functioning or activity level.

Follow-up durations were limited in most of the initial trials. While the research provides insight into short-term changes, there is limited information for long-term outcomes, such as how often the ulcers might reappear after healing. Furthermore, sample sizes were modest in some key studies, meaning the strength of the evidence for certain groups remains insufficient. Subgroup findings are uncertain, particularly for patients with very large or very deep wounds. The evidence contributes to understanding symptom patterns, but the data are still emerging regarding sustained effects outside of the study timeframe.

Frequently Asked Questions (FAQ)

Common questions about Regranex (FAQ)

Q: Can Regranex be used on burns?

A: According to official product information, Regranex is only indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or deeper. The drug's safety and effectiveness have not been established for other wound types, such as burns, pressure ulcers, or venous stasis ulcers. Its purpose is to promote the healing of chronic, open wounds.

Q: Is it normal to feel a tingling sensation after applying the gel?

A: The official reports of side effects include application site reactions such as pain and skin irritation. Postmarketing reports also occasionally mention a burning sensation or tingling feeling at the site of application. Regulatory documents advise consulting a healthcare provider for any concerns related to application site reactions.

Q: Can people with kidney problems use Regranex?

A: Official regulatory documents indicate that the active ingredient in Regranex is absorbed into the body at an insignificant level following topical application to the wound. Because of this negligible systemic absorption, the official prescribing information contains no specific warnings or contraindications related to pre-existing kidney or renal function.

Q: What type of medical professional typically prescribes Regranex?

A: This is a prescription-only medication. Official information describes the drug's use as being initiated and overseen by a physician experienced in managing diabetic wounds. Since Regranex is used as an adjunct to comprehensive ulcer care, the prescribing professional is often a specialist involved in wound management or related care.

Q: Is Regranex only used in a hospital setting?

A: Official instructions for use include detailed application steps that are often carried out at home. These steps involve applying the gel, covering the wound with a dressing, and rinsing the gel off after a specified period of time. This suggests that while it is part of a comprehensive care program, its use is not limited solely to a hospital or clinical setting.

Q: Does Regranex help with scars once the wound is closed?

A: Regranex is specifically indicated to promote the healing of open lower extremity diabetic neuropathic ulcers by stimulating the formation of new tissue. Treatment is intended to continue only until the ulcer is completely healed. Official documents do not address or provide information regarding the drug’s effects on post-closure scarring.

Q: Is Regranex commonly used in wound care centers?

A: Regranex is an adjunct therapy that requires good ulcer care, including wound debridement and pressure relief. Due to the specialized nature of the drug and the comprehensive care required, treatment is typically initiated and monitored by physicians experienced in managing diabetic wounds, such as those working in specialized wound care settings.

Q: Does Regranex contain steroids?

A: The active ingredient in Regranex is becaplermin, which is classified as a recombinant human Platelet-Derived Growth Factor-BB. This is a type of protein, not a steroid. The official list of ingredients in the gel vehicle also does not include any steroids.

Q: What should I do if the gel changes color or consistency?

A: The product is described in official documents as a clear, colorless to straw-colored gel. Changes in the gel's color or consistency should be discussed with a pharmacist or healthcare provider. The product should also not be used past its expiration date or six weeks after first opening.

Q: Why do official documents mention caution about using Regranex near the eyes?

A: The official Medication Guide explicitly instructs users to avoid applying Regranex near or in the mouth, eyes, or vagina. This is a standard safety precaution because the drug is a specialized topical agent designed and approved only for application to the wound surface of the lower extremity.

Q: Is Regranex available in countries outside of the US?

A: Regranex has been available in various countries globally. For example, it was previously authorized for use by the European Medicines Agency (EMA), but that authorization was later withdrawn by the manufacturer. Availability of the product outside of the United States can vary by country and region.

Q: What happens if I accidentally swallow a small amount of Regranex gel?

A: Regranex is intended for topical use only and must not be taken by mouth. Since the systemic absorption of the drug through the skin is considered insignificant, no severe systemic side effects are expected from accidental oral exposure. Regulatory information advises seeking medical assistance following accidental oral exposure.

Q: Is the Regranex tube meant for single-patient use only?

A: Regulatory documents and instructions for use state that a tube of Regranex is intended for use on a single patient only. This rule is in place to help prevent any risk of microbial contamination or spoilage of the product.

How should Regranex be stored and disposed of?

How to Store and Dispose of Regranex (becaplermin) Gel

Regranex gel requires strict cold storage as documented in official regulatory labeling. The product must be stored in a refrigerator at a temperature between 2 C and 8 C (36 F and 46 F) and must not be frozen.

Handling and Stability

The container must be closed tightly after each use to maintain its integrity, and the tube tip should not touch the wound surface during application. The gel must be discarded if the expiration date is passed. After first opening, the product should be discarded within six weeks.